How a specific protein in cancer cells affects immune response and tumor growth
αvβ3-induced epithelial cancer progression via macrophage recruitment
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11066453
This study is looking at how a specific protein called integrin αvβ3 affects cancer growth by influencing immune cells in tumors, and it aims to find new ways to boost the immune system's ability to fight cancer.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11066453 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the integrin αvβ3 in cancer progression, particularly how it influences immune cells within the tumor microenvironment. The study focuses on how tumor cells manipulate immune responses to promote their own growth and how chronic inflammation can lead to increased cancer development. By using animal models, the researchers aim to understand the mechanisms behind the recruitment of tumor-associated macrophages, which suppress the immune system and facilitate tumor progression. The findings could provide insights into new therapeutic strategies targeting this protein to enhance anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers, particularly those involving lung cancer and related inflammatory conditions.
Not a fit: Patients with early-stage cancers or those not expressing the integrin αvβ3 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune response against tumors, potentially improving outcomes for cancer patients.
How similar studies have performed: Previous research has shown that targeting immune cell interactions in the tumor microenvironment can lead to significant advancements in cancer treatment, suggesting this approach has potential.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WETTERSTEN, HIROMI INOUE — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: WETTERSTEN, HIROMI INOUE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, cancer cell, Cancer Induction